Lin K.-F.KUO-HSING CHENWEI-LIEH HUANG2021-08-202021-08-202015-03-010163-8343https://www.scopus.com/inward/record.uri?eid=2-s2.0-84924787775&doi=10.1016%2fj.genhosppsych.2015.01.007&partnerID=40&md5=8eb372f35a015f96f1d2dd0cc2bbd314https://scholars.lib.ntu.edu.tw/handle/123456789/578377Hypocalcemia can induce heterogeneous psychiatric manifestations, and its etiology can be multifactorial. Herein, we describe a patient who had previously undergone resection of parathyroid glands, who presented with extreme anxiety and hypocalcemia after denosumab treatment for cancer-related bone metastasis. The anxiety subsided soon after correction of her serum calcium level. When denosumab is prescribed for patients with predisposing factors of hypocalcemia, such as hypoparathyroidism, clinicians should be aware of symptomatic hypocalcemia. ? 2015 Elsevier Inc.Denosumab; Hypocalcemia; Hypoparathyroidism; Organic anxiety[SDGs]SDG3alprazolam; brotizolam; calcium; capecitabine; clonazepam; denosumab; fentanyl; hydrocortisone; letrozole; lorazepam; mirtazapine; morphine; navelbine; sertraline; zopiclone; bone density conservation agent; denosumab; adult; anxiety; anxiety disorder; Article; bone metastasis; breast cancer; calcium blood level; case report; disease predisposition; female; human; hypocalcemia; hypoparathyroidism; insomnia; middle aged; mood disorder; organic anxiety; organic anxiety; parathyroid gland; anxiety disorder; Bone Neoplasms; breast tumor; chemically induced; complication; hypocalcemia; pathology; secondary; Anxiety Disorders; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Female; Humans; Hypocalcemia; Hypoparathyroidism; Middle Agedjournal article10.1016/j.genhosppsych.2015.01.007257729472-s2.0-84924787775